Salmon Calcitonin is indicated for the treatment of osteoporosis in women who are at least five years postmenopausal, to reduce the risk of vertebral fractures. It can also be used as adjunctive therapy for the management of Paget's disease of bone and hypercalcemia associated with malignancy.

Post Menopausal Osteoporosis (Brittle Bone)

Paget's Disease

Hypercalcaemia/Hypercalcemia (High Calcium)

The dosage and administration of Salmon Calcitonin may vary depending on the specific condition being treated. It is available as an injectable formulation. The recommended dosage for osteoporosis is usually 100 International Units (IUs) injected subcutaneously or intramuscularly once daily. Dosage adjustments may be necessary based on individual patient response and tolerability. It is important to follow the prescribed dosage and the instructions provided by the healthcare professional.

Common side effects associated with Salmon Calcitonin may include:

• Nausea
• Vomiting
• Flushing or warmth of the skin
• Injection site reactions (such as redness, pain, or swelling)
• Hypersensitivity reactions (including rash, itching, or swelling)

Nausea

Vomiting

Flushing

Pain at injection site

Before initiating treatment with Salmon Calcitonin, the following precautions and warnings should be considered:

• Hypersensitivity Reactions: Cases of hypersensitivity reactions, including severe anaphylactic reactions, have been reported with Salmon Calcitonin use. Patients should be closely monitored for signs of allergic reactions during treatment. Discontinue the medication if any signs of a severe allergic reaction (such as difficulty breathing, swelling, or hives) occur and seek immediate medical attention.
• Hypocalcemia: Salmon Calcitonin can cause hypocalcemia (low blood calcium levels) in some patients. Monitoring of serum calcium levels is recommended, especially in patients with pre-existing hypocalcemia or conditions predisposing them to hypocalcemia.
• Pregnancy and Lactation: The safety of Salmon Calcitonin during pregnancy and lactation has not been well established. It should be used during pregnancy or breastfeeding only if the potential benefits outweigh the risks. Consult a healthcare professional before using Salmon Calcitonin in these situations.
• Pediatric Use: The safety and efficacy of Salmon Calcitonin in pediatric patients have not been established. Its use in the pediatric population is not recommended.
• Renal Impairment: Salmon Calcitonin should be used with caution in patients with renal impairment. Dosage adjustments may be necessary based on the degree of renal dysfunction.